Celyad announces pricing of $47.3 million global offering
May 17, 2018 09:02 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 17, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of...
Celyad Announces First Quarter 2018 Business Update
May 15, 2018 16:47 ET
|
Celyad SA
Steady progress in THINK1, SHRINK2 and LINK3 trials MONT-SAINT-GUIBERT, Belgium, May 15, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a...
Celyad announces launch of proposed global offering
May 15, 2018 16:46 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 15, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of...
Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018
May 09, 2018 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 09, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) a clinical-stage biopharmaceutical company focused on the development of...
Celyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK Trials
May 03, 2018 01:00 ET
|
Celyad SA
Celyad achieves important milestone in CYAD-01 treatment evaluation of metastatic colorectal cancer: No toxicity observed to date in first patient enrolled in the SHRINK1 trial (concurrent...
Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient
April 27, 2018 02:30 ET
|
Celyad SA
Case report details first ever reported complete morphologic remission with gene engineered T-cells in a relapsed/refractory AML patient without preconditioning MONT-SAINT-GUIBERT, Belgium, April ...
Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018
March 29, 2018 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, March 29, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of...
Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018
March 22, 2018 16:01 ET
|
Celyad SA
Conference call scheduled for Friday, 23 March, at 2:00 p.m. CET / 9:00 a.m. EDT NKG2D CARs demonstrate validity of the target with the clinical activity observed in solid and hematological cancers...
Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 21, 2017 16:30 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell...
Celyad Announces Third Quarter 2017 Business Update
November 17, 2017 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of...